Sarepta Therapeutics, Inc. (LON:0L35)

Market Cap	4.35B
Revenue (ttm)	1.52B
Net Income (ttm)	187.90M
Shares Out	n/a
EPS (ttm)	1.87
PE Ratio	23.13
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	298
Average Volume	1,316
Open	53.70
Previous Close	53.85
Day's Range	53.54 - 54.72
52-Week Range	53.73 - 155.48
Beta	0.92
RSI	39.92
Earnings Date	May 5, 2025

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1980
• Employees: 1,372
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0L35

Financial Performance

Financial numbers in USD